LFG
LXRX icon

Lazard Frères Gestion’s Lexicon Pharmaceuticals LXRX Stock Holding History

Lazard Frères Gestion’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$119K – 96
2024
Q1 		$119K Buy
+50,000
New +$107K ﹤0.01% 77

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Lazard Frères Gestion's LXRX Position: Q2 2024 in Review

Lazard Frères Gestion sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2024, closing a stake of 50,000 shares — an estimated $119K sold.

Lazard Frères Gestion first reported a position in LXRX in Q1 2024 and held it in 1 quarter. The position peaked at $119K in Q1 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.

  • Lazard Frères Gestion reported no remaining Lexicon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Lazard Frères Gestion sold 50,000 Lexicon Pharmaceuticals shares in Q2 2024, an estimated $119K.
  • Lazard Frères Gestion first reported a position in Lexicon Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Lazard Frères Gestion's Lexicon Pharmaceuticals position peaked at $119K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.

Based on Lazard Frères Gestion's 13F filing for Q2 2024, filed 29 Jul 2024.